<DOC>
	<DOCNO>NCT00426348</DOCNO>
	<brief_summary>statement study hypothesis : effect valsartan patient IgA nephropathy prove , efficacy probucol combination valsartan prove patient IgA nephropathy . This prospective randomized control , double blind pilot study identify efficacy probucol combination valsartan patient IgA nephropathy . The renal function deterioration primary outcome study . The expected study duration 36 month .</brief_summary>
	<brief_title>A Study Antioxidant Probucol Combined With Valsartan Patients With IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients fulfill clinical pathological criterion IgA nephropathy Age : 1860 year Renal biopsy diagnostic IgA nephropathy base immunohistologic stain IgA great equal staining IgG IgM Urinary protein excretion rate within range 12.5g/day Serum creatinine &lt; 265.2umol/L time randomization Patients refuse randomized treatment Patients prefer treatment conventional agent Patients pregnant plan pregnancy Patients pathologically proven severely diffusely proliferative IgA nephropathy crescent glomerulonephritis &gt; = 50 % segmental involvement glomerulus treat agent , immunosuppressive agent steroid Clinical histologic evidence : systemic lupus erythematosus HenochSchonlein purpura cirrhosis chronic active liver disease hepatitis B hepatitis C severe chronic diarrhea active peptic ulcer disease HIV acute renal failure malignant hypertension severe heart diseases malignant tumor systemic infection pregnancy Known contraindication administration probucol valsartan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>IgA nephropathy</keyword>
	<keyword>probucol</keyword>
	<keyword>valsartan</keyword>
	<keyword>treatment</keyword>
	<keyword>antioxidant</keyword>
	<keyword>IGA nephropathyï¼ša kind glomerulonephritis , IgA dominant immunodeposit mesangial area</keyword>
</DOC>